ID: 4121762 Transforming Cardio-Oncology Care with Wearable Technology – Using Smartwatches to Monitor for Arrhythmias in Vulnerable Patient Populations
HeartRhythm
AUGUST 31, 2024
Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes. The incidence of atrial fibrillation (AF) is 10-15% with a median time to occurrence of 5-13 months.
40 
Let's personalize your content